Home >  Investors Relations >  Financial Information >  SEC Filings

News Releases

  • March 7, 2018 at 6:13 PM EST
    ATLANTA , March 7, 2018 /PRNewswire/ -- Fourth Quarter and Recent Business Highlights: Achieved fourth quarter revenues of $52.8 million Achieved double digit revenue growth on a percentage basis in BioGlue ® , On-X, and tissue processing Recorded GAAP net loss of ($3.0) million , or ($0.09) per
  • February 12, 2018 at 5:04 PM EST
    ATLANTA , Feb. 12, 2018 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 fourth quarter and year-end financial results will be released on Wednesday, March 7, 2018 after the market
  • December 1, 2017 at 5:04 PM EST
    ATLANTA , Dec. 1, 2017 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that it has completed its previously announced acquisition of JOTEC AG , a German-based, privately-held developer of
  • November 6, 2017 at 5:04 PM EST
    ATLANTA , Nov. 6, 2017 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that enrollment has started in the Company's BioGlue clinical trial in China.  The results from the trial will serve as
  • October 30, 2017 at 5:30 PM EDT
    ATLANTA , Oct. 30, 2017 /PRNewswire/ --  Third Quarter and Recent Highlights: Announced Definitive Agreement to Acquire JOTEC Accelerated Enrollment in PerClot Clinical Trial Achieved Third Quarter Revenues of $44.0 Million Achieved GAAP Net Income of  $1.3 million , or $0.04 Per Fully Diluted
  • October 17, 2017 at 5:04 PM EDT
    ATLANTA , Oct. 17, 2017 /PRNewswire/ --  CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that 2017 third quarter financial results will be released on Monday, October 30, 2017 after the market closes.  On
  • October 10, 2017 at 5:00 PM EDT
    Provides Access into $2 Billion Global Stent Graft Market with Highly Competitive Technologically Advanced Product Portfolio Adds Robust New Product Pipeline and Significantly Enhances R&D Capabilities Accelerates European Direct Strategy and Meaningfully Expands Cross-Selling Opportunities
  • October 2, 2017 at 8:04 AM EDT
    ATLANTA , Oct. 2, 2017 /PRNewswire/ --   CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced the appointment of Jeffrey H. Burbank to its Board of Directors effective September 29, 2017 .
  • September 18, 2017 at 8:34 AM EDT
    ATLANTA , Sept. 18, 2017 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), a leading medical device and tissue processing company focused on cardiac and vascular surgery, announced today that Pat Mackin , Chairman, President and Chief Executive Officer, will present at two investor conferences in
  • July 24, 2017 at 5:04 PM EDT
    ATLANTA , July 24, 2017 /PRNewswire/ -- Second Quarter Highlights: Revenues Increased Two Percent Year-over-Year to $47.8 Million ; Non-GAAP Revenues Increased Four Percent Year-over-Year Gross Margins were 69 Percent GAAP Net Income was $3.2 Million , or $0.09 Per Fully Diluted Common Share;